PSC
SWTX

Patient Square Capital’s SpringWorks Therapeutics SWTX Stock Holding History

Patient Square Capital’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-93,137
Closed -$3.37M – 23
2024
Q4 		$3.37M Buy
+93,137
New +$3.25M 1.26% 14

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Patient Square Capital's SWTX Position: Q1 2025 in Review

Patient Square Capital sold out of SpringWorks Therapeutics (SWTX) in Q1 2025, closing a stake of 93,137 shares — an estimated $3.37M sold.

Patient Square Capital first reported a position in SWTX in Q4 2024 and held it in 1 quarter. The position peaked at $3.37M in Q4 2024. 306 funds tracked by Wall St. Rank hold SWTX as of Q1 2025.

  • Patient Square Capital reported no remaining SpringWorks Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Patient Square Capital sold 93,137 SpringWorks Therapeutics shares in Q1 2025, an estimated $3.37M.
  • Patient Square Capital first reported a position in SpringWorks Therapeutics in Q4 2024 and held it in 1 quarter.
  • Patient Square Capital's SpringWorks Therapeutics position peaked at $3.37M in Q4 2024.
  • 306 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2025.

Based on Patient Square Capital's 13F filing for Q1 2025, filed 14 May 2025.